Please assess the completion status of the following clinical trial:

Trial Title: A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with chronic kidney disease defined as serum creatinine of 1.5 to 6.0 mg/dL for women and 2.0 to 6.0 mg/dL for men~* glomerular filtration rate (GFR) within 15-60 mL/min~* Subjects on darbepoetin alfa for 3 months or more and with a stable entry hemoglobin level of 12 (plus or minus 1 g/dL~* range 11-13 g/dL)~* Subjects receiving darbepoetin alfa on an every two, three, or four week dosing schedule~* female subjects with a reproductive potential must have a negative ruine pregnancy test within 7days of the first dose of study drug.~Exclusion Criteria:~* No uncontrolled high blood pressure as assessed by the primary physician~* No known hypersensitivity to mammalian cell-derived products~* No known hypersensitivity to human albumin~* Not receiving dialysis or scheduled to receive dialysis during the course of the study~* No severe congestive heart failure (New York Heart Association Class IV)~* No known severe stable or unstable coronary artery disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).